How much does AiRuiKa (Camrelizumab for Injection) Cost& price without insurance in China?
AiRuiKa® is the commercial brand name of Camrelizumab for Injection, a humanized anti-programmed death 1 (anti-PD-1) monoclonal antibody independently developed by Jiangsu Hengrui Pharmaceuticals. It binds to the PD-1 receptor on T lymphocytes, blocks its binding to PD-L1/PD-L2 on tumor cells, reactivates tumor-specific T cell immunity and exerts anti-tumor effects.
Main Indications
Treatment of relapsed or refractory classic Hodgkin lymphoma in adult patients who have received at least two lines of systemic chemotherapy;
Treatment of unresectable hepatocellular carcinoma previously treated with sorafenib or combined chemotherapy;
First-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma combined with chemotherapy;
First-line treatment of metastatic non-squamous non-small cell lung cancer combined with platinum-based chemotherapy;
First-line treatment of metastatic squamous non-small cell lung cancer combined with platinum-based chemotherapy;
Treatment of recurrent or metastatic nasopharyngeal carcinoma.
Common Side Effects
Common mild adverse reactions: Reactive capillary hemangiomas, fever, fatigue, hypothyroidism, rash, pruritus, diarrhea and nausea;
Laboratory abnormalities: Decreased neutrophil count, decreased lymphocyte count and elevated liver transaminases;
Severe but uncommon risks: Immune-related adverse events including pneumonitis, colitis, hepatitis and endocrinopathies, severe infections and infusion-related reactions.
Approval Status in China
AiRuiKa® (Camrelizumab for Injection, 200mg per vial) was officially approved for marketing in China in 2019. It is currently a prescription anti-tumor biologic drug included in China’s Category B medical insurance.
Buy AiRuiKa (Camrelizumab for Injection) online from China and save up to 80% on costs . no insurance needed . compare prices from a certified HongKong pharmacy .with fast shipping. Contact us now on WhatsApp to get the latest prices.
